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Abstract Interaction between epidermal growth factor
receptor (EGFR) signaling with GM3 ganglioside expres-
sion has been previously described. However, little is
known about EGFR and NeuGcGM3 co-expression in
cancer patients and their therapeutic implications. In this
paper, we evaluate the co-expression of EGFR and
NeuGcGM3 ganglioside in tumors from 92 patients and in
two spontaneous lung metastasis models of mice (Lewis
lung carcinoma (3LL-D122) in C57BL/6 and mammary
carcinoma (4T1) in BALB/c). As results, co-expression of
EGFR and NeuGcGM3 ganglioside was frequently
observed in 63 of 92 patients (68 %), independently of
histological subtype. Moreover, EGFR is co-expressed
with NeuGcGM3 ganglioside in the metastasis of 3LL-
D122 and 4T1 murine models. Such dual expression
appears to be therapeutically relevant, since combined
therapy with mAbs against these two molecules synergis-
tically increase the survival of mice treated. Overall, our
results suggest that NeuGcGM3 and EGFR may
coordinately contribute to the tumor cell biology and that
therapeutic combinations against these two targets might
be a valid strategy to explore.
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Introduction
Most epithelial tumors overexpress the EGFR and their
activation is related with cancer progression. However,
tumors exhibit a diverse response to anti-EGFR therapies,
with resistance as common result of the treatment [1].
The N-Acetylneuramic acid (NeuAcGM3) ganglioside,
but not the N-glycolylneuramic acid (NeuGcGM3), is
usually detected in normal human tissues. However, many
human tumors express NeuGcGM3 ganglioside [2–7]. The
expression of NeuGcGM3 have been associated with a
worse prognosis in colon [8] and lung cancer [7, 9]. Dif-
ferential association between EGFR signaling pathway and
GM3 ganglioside expression has been reported [10–13].
Overexpression of GM3 increase the proliferation of car-
cinoma cells (A431) by ERK-independent signaling, in the
presence of urokinase plasminogen activator (uPA) and
their receptor (uPAr) [14]. Conversely, GM3 depletion
increase the EGFR phosphorylation and the ERK-depen-
dent cell proliferation becomes prevalent [14]. These
results provide a rational for a combined treatment tar-
geting simultaneously both EGFR and GM3 mediated
signaling pathways.
The Center of Molecular Immunology (CIM, Havana,
Cuba) have developed several immunotherapeutic projects
targeting separately both EGFR [15, 16] and NeuGcGM3
[17, 18]. Therefore, we evaluate the frequency of co-
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expression of EGFR and NeuGcGM3 ganglioside in human
tumors and in two spontaneous lung metastasis models of
mice (Lewis lung carcinoma (3LL-D122) in C57BL/6 and
mammary carcinoma (4T1) in BALB/c). Moreover, we
perform an initial evaluation of the therapeutic implications
of targeting simultaneously both molecules, in lung
models.
Materials and methods
Patients samples
Sections of formalin-fixed and paraffin-embedded tumor
tissues from 92 patients were taken from the pathology
department of the National Institute of Oncology and
Radiobiology and Dr. ¨Manuel Fajardo¨ General Teaching
Hospital after receiving approved consent by the Ethical
Committee of the institute.
Cell lines
Lewis lung carcinoma (3LL-D122); mouse breast adeno-
carcinoma cells (4T1); human vulva epidermoid carcinoma
(A431, ATCC, CRL-1555) and murine myeloma P3-X63-
Ag8.653 (X63, ATCC, CRL-1580) were cultured in
DMEM: F12 (Life Technologies Inc., Grand Islan, NY)
supplemented with 10 % fetal bovine serum (FBS).
Lung metastasis murine models
Mice female of 6–8 week old female, were purchased from
the Center for Laboratory Animal Production (CEN-
PALAB, Havana, Cuba). Animal’s procedures were per-
formed in accordance with the guidelines stipulated by
Animal Subject Committee Review Board of the CIM and
CIM’’s Institutional Animal Care and Use Committees.
3LL-D122-metastasis model: C57BL/6 mice were injected
into lateral tail veins (i.v.) with 2.5 9 105 of tumor cells.
4T1-metastasis model: BALB/c mice were transplanted
subcutaneously (s.c). into the mammary gland with
1 9 104 of tumor cells. Primary tumor diameters were
measured every 2–3 days with a caliper and tumor volume
(mm3) was determined to the following formula = (minor
diamenter)2 9 (major diameter) 9 p/6. To study overall
survival (OS), animals were monitored every day until the
primary tumor exceeded 20 % of the body mass (4T1-
model) and the signs of malignancy appeared. In parallel
experiments, the mice were sacrificed 21 days (3LL-D122-
model) and 25 days (4T1-model) after tumor implantation
to evaluate lung metastases. Metastatic lung were removed
and metastases were quantified through lung weight,
established as a surrogate of the number and size of
metastasis. Control groups received PBS.
Murine samples
Tumor sections from the metastatic lungs were obtained by
cryostat (SLEE MEDICAL GMBH Co. Mainz, Germany)
and mounted on plus slides. Afterwards, in both cases, the
slides were kept at -20 C until they were used for
immunostaining.
Monoclonal antibodies
Ior egf/R3 (R3m) is a mAb against human EGFR [19]. 7A7
mAb for murine EGFR [20]. 14F7 mAb against
NeuGcGM3 ganglioside and it was used in patients and
murine samples [21]. Regarding the treatment: 14F7 mAb
and 7A7 mAb were administered on days 3, 5, 7, 9, 11 and
13 post-inoculation tumoral. 14F7 mAb was used at doses
of 200 lg and 7A7 mAb (56 lg), both by i.v.
Immunohistochemical staining
The slides were incubated with the appropriately diluted pri-
mary antibody for 1 h at room temperature. Negative controls
were performed by substituting primary for the TBS (Tris/
saline buffer solution). Each staining included a known pos-
itive control: to human EGFR: A431 cells; to murine EGFR:
3LL-D122 and to NeuGcGM3: X63 cells. Breast ductal car-
cinoma is positive tissue for human EGFR and NeuGcGM3.
R3m, 7A7 and 14F7 mAbs were visualized using the kit
Universal Dako LSBA?System-HRP (Dako, K0679) and the
manufacturer’s recommendations were followed. Finally, the
sections were counterstained with Mayer’s hematoxylin.
Evaluation of immunostaining
Results were evaluated by the intensity of immunoreac-
tions and the percentage (%) of the tumor cells displaying
immunoreactivity with the cytoplasm and on the membrane
pattern. The staining intensity was graded on a scale of 0–3
(0, no staining; 1, weak; 2, moderate and 3, strong stain-
ing). The proportion of stained cells was graded on a scale
of 0–3 (0, no staining; 1, 6–25 %; 2, 26–50 % and 3, more
than 50 %). Two independent observers analyzed five
fields in randomly selected tumor areas/animals.
Double immunofluorescence staining
Co-expression of EGFR and NeuGcGM3 ganglioside was
determined by a double staining. R3m or 7A7 mAbs followed
by polyclonal rabbit anti-mouse immunoglobulins/FITC
(Dako, F0232). 14F7 mAb followed by polyclonal goat anti-
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mouse immunoglobulins/RPE (Dako, R0480). Co-expression
was detected by yellow fluorescence using the Olympus BX51
LTD microscope (Olympus Optical Co., Ltd., Japan).
Statistical analyses
Overall survival (OS) analyze was performed according to
the Kaplan–Meier methods. Statistical analysis was carried
out using SPSS (version 11.5, SPSS Inc., Chicago, IL). A p
value, 0.05 was considered statistically significant.
Results
Co-expression of EGFR and NeuGcGM3 molecules
in human primary tumors
Co-expression of EGFR and NeuGcGM3 ganglioside on
tumor samples (63) from 92 patients (68 %) is summarized
in Table 1 and exemplified in Fig. 1. First, EGFR and
NeuGcGM3 expression was analyzed by immunohisto-
chemistry and second, the co-expression of both molecules
was determined by immunofluorescence assay. The inten-
sity of immunoreactions and proportion of stained cells
was variable. A weak to strong intensity staining following
a homogeneous cell membrane pattern in 68 of the 92
(74 %) of EGFR was detected. Similar intensity of
NeuGcGM3 ganglioside expression with plasmatic mem-
brane and cytoplasm staining was observed in 71 (77 %).
The tumors with the greatest number of patients (n[ 6):
NSCLC, nasopharyngeal, colorectal, renal and liver carci-
noma showed co-expression (EGFR/NeuGcGM3) in more
than 50 % of their tumoral cells. Other carcinomas with
fewer patients (n = 2–5) also showed high percentage of
EGFR/NeuGcGM3 positive cells: prostate, ovarian, cervi-
cal, breast carcinoma and glioblastoma multiform. In
addition, co-expression of both EGFR and NeuGcGM3
ganglioside (30-70 %) was observed in others tumors with
Table 1 Co-expression of EGFR and NeuGcGM3 ganglioside in human primary tumors
Histological subtype EGFR NeuGcGM3 Double
positive
Staining
intensity
Positive cells Staining
intensity
Positive cells
0 1 2 3 Total (%) 0 1 2 3 Total (%) Total (%)
NSCLC 13/23 (56) 15/23 (65) 12/23 (52)
Adenocarcinoma
(ADC)
2–3 4 2 2 3 7/11 (64) 1–3 4 1 3 3 7/11 (64) 6/11 (54)
Squamous cell
carcinoma
2 6 1 2 3 6/12 (50) 1–3 4 1 4 3 8/12 (67) 6/12 (50)
Digestive system 30/35 (86) 31/35 (88) 31/35 (88)
Stomach (ADC) 2–3 0 0 2 1 3/3 (100) 2–3 1 0 1 1 2/3 (67) 2/3 (67)
Nasopharyngeal
carcinoma
1–3 4 3 4 3 10/14 (71) 1–3 1 2 3 8 13/14 (93) 10/14 (71)
Colorectal (ADC) 1–3 0 0 2 6 8/8 (100) 1–3 1 0 4 3 7/8 (87) 7/8 (87)
Pancreas (ADC) 2–3 0 0 0 1 1/2 (50) 2–3 0 0 0 2 2/2 (100) 1/2 (50)
Liver 2–3 0 0 1 7 8/8 (100) 2–3 1 0 4 3 7/8 (87) 7/8 (87)
Urogenital system 16/23 (69) 19/23 (83) 14/23 (61)
Prostate 1–3 2 0 1 2 3/5 (60) 1–3 1 0 1 3 4/5 (80) 3/5 (60)
Ovary 2 1 1 1 1 4/5 (80) 3 3 1 1 0 2/5 (40) 2/5 (40)
Cervical carcinoma 3 0 0 0 2 2/2 (100) 3 0 0 0 2 2/2 (100) 2/2 (100)
Breast carcinoma 3 3 0 0 2 2/5 (40) 3 0 0 3 2 5/5 (100) 2/5 (40)
Renal cell carcinoma 1–3 1 0 3 2 5/6 (83) 3 0 3 2 1 6/6 (100) 5/6 (83)
Nervous system 5/5 (100) 3/5 (60) 3/5 (60)
Glioblastoma
multiforme
3 0 0 3 2 5/5 (100) 2 0 2 1 0 3/5 (60) 3/5 (60)
2/3 (67) 1/3 (33) 1/3 (33)
Sarcomas 1–2 1 2 0 0 2/3 (67) 1 2 1 0 0 1/3 (33) 1/3 (33)
Haemopoietic system 2/3 (67) 2/3 (67) 2/3 (67)
Non-hodking
lymphoma
1 1 2 0 0 2/3 (67) 1 1 2 0 0 2/3 (67) 2/3 (67)
Staining intensity: 0, no staining; 1, weak; 2, moderate and 3, strong staining
Positive cells: 0, no staining; 1, 6–25 %; 2, 26–50 % and 3, more than 50 %
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small number of patients but of different origin as sarcomas
(n = 3) and non-Hodgkin lymphomas (n = 3). Represen-
tative image of co-expression of EGFR and NeuGcGM3
molecules is observed in Fig. 2.
Co-expression of EGFR with NeuGcGM3 molecules
in murine models
First, EGFR and NeuGcGM3 ganglioside expression on
tumor sections from Lewis Lung carcinoma (3LL-D122)
and breast carcinoma (4T1) were characterized by
immunohistochemistry assay: Table 2 and Fig. 3. EGFR
and NeuGcGM3 ganglioside expression was detectable in
30 of 30 (100 %) animals in both models (Table 2). EGFR
and NeuGcGM3-immunostaining was located in the plas-
matic membrane and/or cytoplasm staining finely granular
pattern (Fig. 2: 3LL-model (a and b) and 4T1-model (d and
e). Table 2 shows a moderate to strong staining of EGFR
and weak to strong intensity to NeuGcGM3 in 3LL-D122
model. Most specimens had strong intensity to EGFR (17
of 30 animals, 57 %) and to NeuGcGM3 (14, 47 %). 4T1-
model showed a weak to strong reactivity of EGFR and
NeuGcGM3 (Table 2). The intensity of EGFR expression
in 13 (44 %) of 30 animals is strong while the most animals
14 (47 %) shown a weak reactivity to NeuGcGM3 gan-
glioside. Double-expression of EGFR (e) and NeuGcGM3
(h) was detected in both models, Fig. 3.
Fig. 1 Images of the staining intensity of EGFR and NeuGcGM3
ganglioside in five different patients. These five patients illustrate the
most frequent classes observed in our study. Left column shows
Hematoxylin and eosin (H&E)-stained tumor tissue sections. Middle
and right column show respectively the EGFR and NeuGcGM3
expression (brown color). Each row corresponds to the individual
patient data specified on the left. EGFR was identified with Ior/egf/r3
mAb and it was mainly located in the cell membrane of malignant
cells. NeuGcGM3 ganglioside expression was identified with 14F7
mAb and it was located in cell membrane and cytoplasmatic cell.
Counterstaining with Mayer’s Hematoxylin (blue color). White
bar = 50 lm, Black bar = 100 lm. (Color figure online)
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Therapeutic implications of EGFR and NeuGcGM3
expression in murine models
To explore the therapeutic impact of targeting simultane-
ously EGFR and NeuGcGM3 molecules in tumors, we treat
3LL (Fig. 4a–c) or 4T1 (Fig. 4d–g) metastasis-bearing
mice with a combination of 7A7 mAb with 14F7 mAb. The
survival behavior by monotherapies effect was similar to
control group (Fig. 4b, e). However, a significant increase
was observed by combined therapy (log rank p\ 0.05)
(Fig. 4b, e). 3LL-model showed a 30 % of the mice remain
alive (Fig. 4b). 4T1-model showed a similar result (25 %)
(Fig. 4e). In parallel experiments, the effect of combined
therapy on lungs weight and/or primary tumor was evalu-
ated at day 21 (3LL) or day 25 (4T1) post-tumor inocula-
tion. In 3LL-model, 7A7 mAb and combined therapy
reduce the lungs weight compared with 14F7 mAb and
control group Fig. 4c. However, not difference was
observed between them. Regarding 4T1-model, neither
individual nor combined treatment had impact on primary
tumor (Fig. 4f). In addition, only combined therapy
showed a reduction of the lungs weight compare with
control group (Fig. 4g).
Discussion
In this paper, we report for the first time the co-expression
of EGFR and NeuGcGM3 ganglioside in different human
tumors. In fact, more than 50 % of co-expression of EGFR
and NeuGcGM3 from 15 histological subtypes was
observed. Our results suggest that it is a frequent phe-
nomenon and thus may support diagnostic considerations.
Recently, our colleagues at CIM confirm that the expres-
sion of NeuGcGM3 or EGFR alone was associated with
poor OS in NSCLC patients [9]. However, the expression
of both targets in the same tumor sample was related with
an even poorer prognosis in these patients [9]. On the other
hand, the heterogeneity of EGFR and NeuGcGM3 gan-
glioside expression (over a range of negative to strong
immunostaining and more than 50 % of positive cells) was
consistent with others reports by each molecules, inde-
pendently: EGFR [22, 23] or NeuGcGM3 [2, 7, 8]. In
addition, this differential expression pattern implies
heterogeneity within individual tumor and may be reflected
in the biological behavior of these tumors.
To explore a possible relationship between EGFR and
NeuGcGM3 in cancer, we first evaluate their expression in
Table 2 Co-expression of EGFR and NeuGcGM3 ganglioside in murine models
EGFR NeuGcGM3 Double
positive
Positive cells Positive cells
Metastasis
model
Staining
intensity
0 1 2 3 Total (%) Staining
intensity
0 1 2 3 Total (%) Total (%)
3LL-D122-cells 2–3 0 0 1 29 30/30 (100) 1–3 0 1 3 26 30/30 (100) 30/30 (100)
4T1-cells 1–3 0 0 2 28 30/30 (100) 1–3 0 2 9 19 30/30 (100) 30/30 (100)
Staining intensity: 0, no staining; 1, weak; 2, moderate and 3, strong staining
Positive cells: 0, no staining; 1, 6-25 %; 2, 26-50 % and 3, more than 50 %
Fig. 2 Co-expression of EGFR and NeuGcGM3 ganglioside in human
non-small cell lung cancer (poorly differentiated ductal adenocarci-
noma). The co-expression of EGFR and NeuGcGM3 was evaluated by
a double immunofluorescence staining. Expression of both molecules
was located on plasmatic membrane. EGFR-positive section (green).
NeuGcGM3 ganglioside-positive section (red). The yellow colour in
merged images identifies co-expression of both molecules on tumour
sections (merged). Scale bars = 100 lm. (Color figure online)
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two models of spontaneous lung metastasis in mice: Lewis
lung carcinoma (3LL-D122) and mammary carcinoma
(4T1). We confirm a high EGFR expression in 3LL-D122
and 4T1-metastatic models by immunohistochemistry
score. Regarding to NeuGcGM3 expression, all animals
showed a positive tumor cells, in both models. Previously,
Labrada et al. showed the increased expression of
NeuGcGM3 from primary tumors to metastatic lesions in
3LL-D122 tumor model [24]. Anti-metastatic effect of
NeuGcGM3/VSSP vaccine which targeting this gan-
glioside was observed in this lung model, previously
[24, 25]. Here, we described for the first time, a positive
staining of NeuGcGM3 expression in lung metastasis
induced by 4T1-cells, as second model. Similarly, to 3LL-
D122, 4T1-cells are negative to NeuGcGM3 ganglioside
expression, in vitro (data not shown). Moreover, the
intensity of NeuGcGM3 expression was slightly lower than
metastasis from 3LL-model. Future studies going on car-
rying out to characterize the expression of NeuGcGM3 in
others organs colonized by 4T1-cells different methods.
Interestingly, EGFR and NeuGcGM3 ganglioside are co-
expressed at the plasmatic membrane in both models.
These murine scenarios are a useful tool for exploring
therapeutic combinations.
Second step, the combination of 7A7 mAb (anti-EGFR)
and 14F7 mAb (anti-NeuGcGM3) exhibited a synergistic
therapeutic effect on the OS in 3LL-D122 or 4T1 lung
metastasis-bearing mice. Anti-tumor effect of the individ-
ual therapies with 7A7 mAb [20, 26, 27] and 14F7 mAb
[21, 28] has been previously reported. Survival benefits of
Fig. 3 Co-expression of EGFR with NeuGcGM3 molecules on lung
metastasis. C57BL/6 mice bearing the Lewis Lung carcinoma (3LL-
D122-model) or BALB/c mice bearing the breast carcinoma (4T1-
model). Histologic section of representative lung metastasis originating
from 3LL (a) and 4T1-model (b) by hematoxilin and eosin staining (H/
E). Metastatic tumors throughout the lung parenchyma in both lung
models. EGFR (c) and NeuGcGM3 (d) expression on 3LL-D122 or
4T1 (f and h) tumor sections were characterized by immunostaining
assay. Co-expression of both molecules on lung sections was evaluated
by a double immunofluorescence method: 3LL-model (e) and 4T1-
model (h). EGFR-positive section (green). NeuGcGM3 ganglioside-
positive section (red). The yellow color identifies co-expression of both
molecules on tumor cells (merged) in 3LL-model (e) and 4T1-model
(h). White bars = 100 lm. (Color figure online)
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14F7 mAb were only observed in tumor models from
hematological malignancies. The combination therapy
effect in OS of 4T1-model was smaller compared with the
results in 3LL-model, that fact could be connected with the
persistence of the primary tumor or heterogeneous
expression of NeuGcGM3 in lung metastases.
The approach was the combination of the tumor-cell
oncosis and antibody dependent cell-mediated cytotoxicity by
14F7 mAb [28, 29] with the inhibition of proliferation, pro-
apoptosis effect and the involvement of T cells in the antitu-
mor activity of 7A7 mAb [20, 26, 27]. The survival data could
be support by complementary mechanisms mentioned before.
Our data are agree with others combined therapies based in
monoclonal antibodies [30, 31]. These results could be
translated to clinical scenery as the opportunity to combine
anti-NeuGcGM3 therapy with Nimotuzumab (Ior egf/r3, anti-
EGFR mAb) that have been demonstrating safety during long
period of treatments [32, 33].
In summary, our results suggest that co-expression of
EGFR and NeuGcGM3 is frequent in human tumors. These
two molecules might coordinately contribute to the tumor
cell biology and therefore the combinations of therapies
against these two targets might be a valid strategy to
explore in the clinic. The impact of EGFR and NeuGcGM3
co-expression as a prognosis factor in human tumors will
are exploring, and the mechanisms mediating the syner-
gistic effect of the combination therapy shall be further
evaluated.
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Fig. 4 Combinatorial targeted therapy to the EGFR and NeuGcGM3
ganglioside in two lung metastasis models of mice: Lewis lung
carcinoma (3LL-D122) in C57BL/6 (a-c) and mammary carcinoma
(4T1) in BALB/c (d-g) . Mice were challenged i.v. (2.5 9 105) with
3LL or subcutaneously (1 9 104) with 4T1 cells. Administration of
schedule with 7A7 or 14F7 mAbs (i.v.) is indicated in schematic
representation of metastasis assays (a and d). To analyze the
percentage of survival, animals (n = 10 per group) of both models
were monitored every day. Kaplan–Meier curves of overall are
showed for each metastasis assay, (p\ 0.05, Log-rank test).
Pulmonary metastases were measured as lung weight on both lung
metastasis models: 3LL-model (c) and 4T1-model (g). Normal lung
weight value is indicated (dashes lines). Primary tumor volume in
4T1-model (f). Each point represents mean ± SD of lung weight per
animals in each group of mice (c and f). One representative
experiment out of three performed experiments is shown in each case
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